tiprankstipranks
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
US Market

Black Diamond Therapeutics (BDTX) Stock Forecast & Price Target

Compare
1,419 Followers
See the Price Targets and Ratings of:

BDTX Financial Forecast

BDTX Earnings Forecast

Next quarter’s earnings estimate for BDTX is -$0.31 with a range of -$0.36 to -$0.25. The previous quarter’s EPS was -$0.28. BDTX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.98% of the time in the same period. In the last calendar year BDTX has Outperformed its overall industry.
Next quarter’s earnings estimate for BDTX is -$0.31 with a range of -$0.36 to -$0.25. The previous quarter’s EPS was -$0.28. BDTX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.98% of the time in the same period. In the last calendar year BDTX has Outperformed its overall industry.
No data currently available

BDTX Sales Forecast

Next quarter’s sales forecast for BDTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BDTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.03% of the time in the same period. In the last calendar year BDTX has Preformed in-line its overall industry.
Next quarter’s sales forecast for BDTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BDTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.03% of the time in the same period. In the last calendar year BDTX has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus
$18$16
Buy
601.75%
Upside
Reiterated
11/06/24
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
TD Cowen
Buy
Reiterated
11/05/24
Promising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond Therapeutics
Raymond James
$20
Buy
777.19%
Upside
Reiterated
11/05/24
H.C. Wainwright
$11
Buy
382.46%
Upside
Reiterated
11/05/24
Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Piper Sandler
$15
Buy
557.89%
Upside
Assigned
10/08/24
Black Diamond Therapeutics (BDTX) Gets a Buy from Piper Sandler
Wedbush
$16
Buy
601.75%
Upside
Reiterated
10/08/24
Black Diamond Therapeutics (BDTX) Receives a Buy from Wedbush
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Black Diamond Therapeutics

Which Analyst Should I Follow If I Want to Buy BDTX and Sell After:
1 Month
xxx
Success Rate
5/9 ratings generated profit
56%
Average Return
+5.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +5.00% per trade.
3 Months
xxx
Success Rate
6/11 ratings generated profit
55%
Average Return
+9.71%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +9.71% per trade.
1 Year
Joseph CatanzaroPiper Sandler
Success Rate
3/8 ratings generated profit
38%
Average Return
-13.70%
assigned a buy rating 5 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -13.70% per trade.
2 Years
xxx
Success Rate
2/11 ratings generated profit
18%
Average Return
-29.74%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -29.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BDTX Analyst Recommendation Trends

Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
7
7
12
13
15
Buy
0
1
2
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
14
16
18
In the current month, BDTX has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BDTX average Analyst price target in the past 3 months is $16.00.
Each month's total comprises the sum of three months' worth of ratings.

BDTX Stock Forecast FAQ

What is BDTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Black Diamond Therapeutics’s 12-month average price target is $16.00.
    What is BDTX’s upside potential, based on the analysts’ average price target?
    Black Diamond Therapeutics has 601.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BDTX a Buy, Sell or Hold?
          Black Diamond Therapeutics has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Black Diamond Therapeutics’s price target?
            The average price target for Black Diamond Therapeutics is $16.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $16.00. The average price target represents 601.75% Increase from the current price of $2.28.
              What do analysts say about Black Diamond Therapeutics?
              Black Diamond Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of BDTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis